@article{ef1e6cbe8f3746dd96a6a7ca9962b9c6,
title = "High-risk childhood acute lymphoblastic leukemia in first remission treated with novel intensive chemotherapy and allogeneic transplantation",
abstract = "Children with acute lymphoblastic leukemia (ALL) and high minimal residual disease (MRD) levels after initial chemotherapy have a poor clinical outcome. In this prospective, single arm, Phase 2 trial, 111 Dutch and Australian children aged 1-18 years with newly diagnosed, t(9;22)-negative ALL, were identified among 1041 consecutively enrolled patients as high risk (HR) based on clinical features or high MRD. The HR cohort received the AIEOP-BFM (Associazione Italiana di Ematologia ed Oncologia Pediatrica (Italy)-Berlin-Frankfurt- M{\"u}nster ALL Study Group) 2000 ALL Protocol I, then three novel HR chemotherapy blocks, followed by allogeneic transplant or chemotherapy. Of the 111 HR patients, 91 began HR treatment blocks, while 79 completed the protocol. There were 3 remission failures, 12 relapses, 7 toxic deaths in remission and 10 patients who changed protocol due to toxicity or clinician/parent preference. For the 111 HR patients, 5-year event-free survival (EFS) was 66.8% (±5.5) and overall survival (OS) was 75.6% (±4.3). The 30 patients treated as HR solely on the basis of high MRD levels had a 5-year EFS of 63% (±9.4%). All patients experienced grade 3 or 4 toxicities during HR block therapy. Although cure rates were improved compared with previous studies, high treatment toxicity suggested that novel agents are needed to achieve further improvement.",
keywords = "Acute lymphoblastic leukemia, Bone marrow transplant, Childhood, Drug toxicity, MRD testing",
author = "Marshall, {G. M.} and {Dalla Pozza}, L. and R. Sutton and A. Ng and {De Groot-Kruseman}, {H. A.} and {Van Der Velden}, {V. H.} and Venn, {N. C.} and {Van Den Berg}, H. and {De Bont}, {E. S.J.M.} and {Maarten Egeler}, R. and Hoogerbrugge, {P. M.} and Kaspers, {G. J.L.} and Bierings, {M. B.} and {Van Der Schoot}, E. and {Van Dongen}, J. and T. Law and S. Cross and H. Mueller and {De Haas}, V. and M. Haber and T. R{\'e}v{\'e}sz and F. Alvaro and R. Suppiah and Norris, {M. D.} and R. Pieters",
note = "Funding Information: We thank Prof Martin Schrappe and the I-BFM for their support. This work was supported by the National Health and Medical Research Council of Australia, Cancer Council New South Wales, Steven Walter Children{\textquoteright}s Cancer Foundation, Cancer Institute New South Wales and Leukemia Foundation. Funding Information: Some of the clinical trial costs were funded by grants from Cancer Council New South Wales and Cancer Institute New South Wales, while some of the MRD assay costs were funded by the Australian National Health and Medical Research Council (NHMRC). These funding bodies had no role in study design, data collection, data analysis, data interpretation or writing of this report. The authors had full access to the data and final responsibility for the decision to submit for publication. The study was registered with the NHMRC{\textquoteright}s Australian Clinical Trials Registry and had a reference number of ACTRN12607000302459.",
year = "2013",
month = jul,
doi = "10.1038/leu.2013.44",
language = "English",
volume = "27",
pages = "1497--1503",
journal = "Leukemia",
issn = "0887-6924",
publisher = "Springer Nature",
number = "7",
}